H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on uniQure (QURE – Research Report) today and set a price target of $30.00. The company’s shares opened today at $6.03.
Trucchio covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Immunocore Holdings, and Oncolytics Biotech. According to TipRanks, Trucchio has an average return of -21.4% and a 25.45% success rate on recommended stocks.
In addition to H.C. Wainwright, uniQure also received a Buy from William Blair’s Sami Corwin in a report issued yesterday. However, on the same day, Wells Fargo maintained a Hold rating on uniQure (NASDAQ: QURE).
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $28.26 and a one-year low of $5.49. Currently, uniQure has an average volume of 1.18M.
Based on the recent corporate insider activity of 61 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of QURE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
uniQure (QURE) Company Description:
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
Read More on QURE:
- uniQure expects cash to fund operations into 2Q27
- uniQure reports Q3 EPS ($1.88), consensus (85c)
- uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
- uniQure N.V. (QURE) Q3 Earnings Cheat Sheet
- uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
